An introduction to the expected domestic launch time and approval progress of ruxolitinib cream (Opzelura)

Ruxolitinib cream (Opzelura) is a new type of JAK inhibitor, mainly used to treat skin diseases such as moderate to severe vitiligo and atopic dermatitis. The drug blocks inflammatory factors and immune-mediated skin damage by inhibiting the Janus kinase (JAK) signaling pathway, thereby promoting pigment recovery and reducing inflammatory reactions. In recent years, ruxolitinib cream has shown good efficacy and safety in overseas clinical studies, attracting widespread attention from domestic patients and physicians.

In terms of domestic marketing approval, ruxolitinib cream is still in the clinical registration or application stage and has not yet been formally approved by the China National Medical Products Administration (NMPA). Therefore, domestic patients are temporarily unable to purchase the drug through formal channels. Pharmaceutical companies are actively advancing the clinical data submission and approval process in order to obtain marketing authorization as soon as possible. Once approved for marketing, it will provide new treatment options for patients with vitiligo and atopic dermatitis.

Currently, if domestic patients want to use ruxolitinib cream, they can only purchase it through overseas channels. The price of foreign original drugs is relatively high, usually as high as more than 10,000 yuan, and they need to be purchased through formal prescriptions or overseas pharmacies. For patients with limited financial conditions, some overseas generic drugs have become viable alternatives. For example, the price of generic drugs in Bangladesh is about a few hundred yuan, and the ingredients of the drugs are basically the same as the original drugs, which can reduce the burden of medication to a certain extent.

Overall, the prospects for the domestic launch of ruxolitinib cream are still progressing. While waiting for approval, patients should pay attention to the latest domestic approval developments and evaluate whether to obtain drugs through overseas channels under the guidance of a doctor. At the same time, when purchasing overseas drugs, you need to ensure that they come from legitimate sources and avoid buying fake and inferior drugs to ensure drug safety and therapeutic effect. With the progress of approval and launch in the future, ruxolitinib cream is expected to become an important choice for the treatment of vitiligo and atopic dermatitis in China.

Reference materials:https://www.drugs.com/